US5439686A
(en)
*
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
US6964946B1
(en)
*
|
1995-10-26 |
2005-11-15 |
Baker Norton Pharmaceuticals, Inc. |
Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
|
US6245805B1
(en)
*
|
1995-10-26 |
2001-06-12 |
Baker Norton Pharmaceuticals, Inc. |
Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
|
US8137684B2
(en)
|
1996-10-01 |
2012-03-20 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
US20030087954A1
(en)
*
|
1997-01-07 |
2003-05-08 |
Sonus Pharmaceuticals, Inc. |
Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
|
US20030105156A1
(en)
*
|
1997-01-07 |
2003-06-05 |
Nagesh Palepu |
Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
|
US6458373B1
(en)
*
|
1997-01-07 |
2002-10-01 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6727280B2
(en)
|
1997-01-07 |
2004-04-27 |
Sonus Pharmaceuticals, Inc. |
Method for treating colorectal carcinoma using a taxane/tocopherol formulation
|
US8853260B2
(en)
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
GB9715759D0
(en)
*
|
1997-07-26 |
1997-10-01 |
Danbiosyst Uk |
New emulsion formulations
|
IL131217A0
(en)
*
|
1998-03-10 |
2001-01-28 |
Napro Biotherapeutics Inc |
Novel methods and compositions for delivery of taxanes
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
US20030059465A1
(en)
*
|
1998-05-11 |
2003-03-27 |
Unger Evan C. |
Stabilized nanoparticle formulations of camptotheca derivatives
|
US7030155B2
(en)
*
|
1998-06-05 |
2006-04-18 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6241969B1
(en)
*
|
1998-06-26 |
2001-06-05 |
Elan Corporation Plc |
Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
|
US6174547B1
(en)
*
|
1999-07-14 |
2001-01-16 |
Alza Corporation |
Dosage form comprising liquid formulation
|
EP1117384A1
(en)
*
|
1998-10-01 |
2001-07-25 |
Elan Pharma International Limited |
Controlled release nanoparticulate compositions
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US6428814B1
(en)
*
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
US7521068B2
(en)
*
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
US6071952A
(en)
*
|
1998-12-02 |
2000-06-06 |
Mylan Pharmaceuticals, Inc. |
Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
|
MXPA01005884A
(es)
*
|
1998-12-11 |
2002-04-24 |
Pharmasolutions Inc |
Composiciones auto-emulsionantes para medicamentos escasamente solubles en agua.
|
NZ512599A
(en)
|
1998-12-30 |
2003-10-31 |
Dexcel Ltd |
Formulation for cyclosporin administration featuring a hydrophilic solvent and a surfactant with a HLB of less than 5
|
AU4053700A
(en)
*
|
1999-04-02 |
2000-10-23 |
Washington State University Research Foundation |
Enhanced tissue and subcellular delivery of vitamin e compounds
|
US20080070981A1
(en)
|
2000-02-23 |
2008-03-20 |
Henryk Borowy-Borowski |
Water-soluble compositions of bioactive lipophilic compounds
|
US6632443B2
(en)
|
2000-02-23 |
2003-10-14 |
National Research Council Of Canada |
Water-soluble compositions of bioactive lipophilic compounds
|
US6045826A
(en)
|
1999-04-02 |
2000-04-04 |
National Research Council Of Canada |
Water-soluble compositions of bioactive lipophilic compounds
|
DE60004191T2
(de)
*
|
1999-04-13 |
2004-04-22 |
Leo Pharma A/S |
Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung
|
KR20070058028A
(ko)
*
|
1999-05-24 |
2007-06-07 |
소너스파머슈티칼즈인코포레이티드 |
난용성 약물용 에멀젼 부형제
|
KR100754352B1
(ko)
*
|
1999-05-24 |
2007-08-31 |
소너스파머슈티칼즈인코포레이티드 |
난용성 약물용 에멀젼 부형제의 제조방법
|
EP1479382A1
(en)
*
|
1999-06-18 |
2004-11-24 |
IVAX Research, Inc. |
Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
|
US20090104273A1
(en)
*
|
1999-06-22 |
2009-04-23 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US20030236236A1
(en)
*
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US6982281B1
(en)
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
MXPA02003203A
(es)
*
|
1999-09-27 |
2004-03-16 |
Sonus Pharma Inc |
Composiciones terapeuticas solubles en tocol.
|
US6136846A
(en)
|
1999-10-25 |
2000-10-24 |
Supergen, Inc. |
Formulation for paclitaxel
|
US6828346B2
(en)
*
|
1999-10-25 |
2004-12-07 |
Supergen, Inc. |
Methods for administration of paclitaxel
|
FR2803203B1
(fr)
*
|
1999-12-31 |
2002-05-10 |
Fournier Ind & Sante |
Nouvelles formulations galeniques du fenofibrate
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
AU2001225432A1
(en)
*
|
2000-01-20 |
2001-07-31 |
Supratek Pharma, Inc. |
Novel podophyllotoxin compositions
|
US6589968B2
(en)
|
2001-02-13 |
2003-07-08 |
Kosan Biosciences, Inc. |
Epothilone compounds and methods for making and using the same
|
US8618085B2
(en)
*
|
2000-04-28 |
2013-12-31 |
Koasn Biosciences Incorporated |
Therapeutic formulations of desoxyepothilones
|
US20040156872A1
(en)
*
|
2000-05-18 |
2004-08-12 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
GB0016876D0
(en)
*
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Novel formulation
|
ES2238050T3
(es)
*
|
2000-07-24 |
2005-08-16 |
PHARMACIA & UPJOHN COMPANY LLC |
Sistemas emulsionantes de liberacion de farmacos para farmacos lipofilos extremadamente insolubles en agua.
|
US7198795B2
(en)
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
AU2001293177A1
(en)
*
|
2000-09-27 |
2002-04-08 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
AUPR549901A0
(en)
|
2001-06-06 |
2001-07-12 |
Vital Health Sciences Pty Ltd |
Topical formulation containing tocopheryl phosphates
|
BRPI0115953B8
(pt)
*
|
2000-11-14 |
2021-05-25 |
Vital Health Sciences Pty Ltd |
complexos de derivados de fosfato
|
MXPA03004546A
(es)
*
|
2000-11-22 |
2003-09-10 |
Rxkinetix Inc |
Tratamiento de mucositis.
|
AU2002239282A1
(en)
*
|
2000-11-28 |
2002-06-11 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
|
AU1987802A
(en)
*
|
2000-11-29 |
2002-06-11 |
Lyotropic Therapeutics Llc |
Solvent systems for pharmaceutical agents
|
ES2316489T3
(es)
*
|
2000-12-05 |
2009-04-16 |
Childrens Hospital Los Angeles |
Composiciones farmaceuticas de fenretinida que tienen biodisponibilidad aumentada y metodos de uso de las mismas.
|
IN188917B
(instruction)
*
|
2000-12-07 |
2002-11-23 |
Bharat Surums & Vaccines Ltd |
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US20050048126A1
(en)
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
US6893859B2
(en)
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
AU2002317053B2
(en)
|
2001-07-27 |
2004-08-05 |
Vital Health Sciences Pty Ltd |
Dermal therapy using phosphate derivatives of electron transfer agents
|
AUPR684801A0
(en)
*
|
2001-08-06 |
2001-08-30 |
Vital Health Sciences Pty Ltd |
Supplement therapy
|
US20030099674A1
(en)
*
|
2001-08-11 |
2003-05-29 |
Chen Andrew X. |
Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
WO2003026611A2
(en)
|
2001-09-26 |
2003-04-03 |
Baxter International Inc. |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
US6858227B1
(en)
|
2001-11-21 |
2005-02-22 |
Sonus Pharmaceuticals, Inc. |
Vitamin E conjugates
|
US20040092428A1
(en)
*
|
2001-11-27 |
2004-05-13 |
Hongming Chen |
Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
|
CN100391464C
(zh)
*
|
2001-12-03 |
2008-06-04 |
诺瓦西股份有限公司 |
含活性维生素d化合物的药物组合物
|
AU2002353118A1
(en)
*
|
2001-12-11 |
2003-07-24 |
Dor Biopharma, Inc. |
Lipid particles and suspensions and uses thereof
|
CN1604772A
(zh)
*
|
2001-12-13 |
2005-04-06 |
生命健康科学有限公司 |
化合物的透皮转运
|
DK1471887T3
(da)
|
2002-02-04 |
2010-06-07 |
Elan Pharma Int Ltd |
Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
|
US6683194B2
(en)
*
|
2002-02-05 |
2004-01-27 |
Sonus Pharmaceuticals, Inc. |
Tocopherol derivatives
|
US7635463B2
(en)
*
|
2002-02-27 |
2009-12-22 |
Pharmain Corporation |
Compositions for delivery of therapeutics and other materials
|
JP2005524657A
(ja)
*
|
2002-02-27 |
2005-08-18 |
ファーメイン, エルティーディー. |
治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
|
EP1340497A1
(en)
*
|
2002-03-01 |
2003-09-03 |
Novagali Sas |
Self emulsifying drug delivery systems for poorly soluble drugs
|
WO2003074027A2
(en)
*
|
2002-03-01 |
2003-09-12 |
Novagali Pharma Sa |
Self emulsifying drug delivery systems for poorly soluble drugs
|
US6825229B2
(en)
|
2002-03-07 |
2004-11-30 |
Blanchette Rockefeller Neurosciences Institute |
Methods for Alzheimer's Disease treatment and cognitive enhancement
|
US20080004332A1
(en)
*
|
2002-03-07 |
2008-01-03 |
Alkon Daniel L |
Methods for alzheimer's disease treatment and cognitive enhancement
|
US20050065205A1
(en)
*
|
2002-03-07 |
2005-03-24 |
Daniel Alkon |
Methods for Alzheimer's disease treatment and cognitive enhance
|
AU2003230691A1
(en)
*
|
2002-03-20 |
2003-10-08 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
US7101576B2
(en)
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
KR20100110378A
(ko)
|
2002-05-24 |
2010-10-12 |
안지오테크 인터내셔날 아게 |
의료용 임플란트를 피복하기 위한 조성물 및 방법
|
FR2840614B1
(fr)
*
|
2002-06-07 |
2004-08-27 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
|
CA2492488A1
(en)
*
|
2002-07-16 |
2004-01-22 |
Elan Pharma International, Ltd. |
Liquid dosage compositions of stable nanoparticulate active agents
|
CA2493878C
(en)
|
2002-07-30 |
2013-07-23 |
Wyeth |
Parenteral formulations containing a rapamycin hydroxyester
|
AU2002950713A0
(en)
|
2002-08-09 |
2002-09-12 |
Vital Health Sciences Pty Ltd |
Carrier
|
US7718189B2
(en)
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
DE60330703D1
(de)
|
2002-11-07 |
2010-02-04 |
Kosan Biosciences Inc |
Trans-9,10-dehydroepothilon c und d, analoga davon und verfahren zu deren herstellung
|
KR100507771B1
(ko)
*
|
2002-11-08 |
2005-08-17 |
한미약품 주식회사 |
난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
|
US20050026877A1
(en)
*
|
2002-12-03 |
2005-02-03 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
EP1585548B1
(en)
|
2002-12-09 |
2018-06-27 |
Abraxis BioScience, LLC |
Compositions and methods of delivery of pharmacological agents
|
US20040115287A1
(en)
*
|
2002-12-17 |
2004-06-17 |
Lipocine, Inc. |
Hydrophobic active agent compositions and methods
|
KR100502821B1
(ko)
|
2002-12-26 |
2005-07-22 |
이호영 |
구리산화물 또는 구리 나노와이어로 이루어진 전자방출팁의 저온 형성 방법 및 이 방법에 의해 제조된 전자방출팁을 포함하는 디스플레이 장치 또는 광원
|
ES2376875T3
(es)
*
|
2003-02-14 |
2012-03-20 |
Children's Hospital & Research Center At Oakland |
Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo
|
US20050196370A1
(en)
*
|
2003-03-18 |
2005-09-08 |
Zhi-Jian Yu |
Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
|
US20040185068A1
(en)
*
|
2003-03-18 |
2004-09-23 |
Zhi-Jian Yu |
Self-emulsifying compositions, methods of use and preparation
|
US20060251685A1
(en)
*
|
2003-03-18 |
2006-11-09 |
Zhi-Jian Yu |
Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
|
WO2004091506A2
(en)
*
|
2003-04-10 |
2004-10-28 |
Ivax Research, Inc. |
Taxane-based compositions and methods of use
|
US7485671B2
(en)
|
2003-05-16 |
2009-02-03 |
Velocys, Inc. |
Process for forming an emulsion using microchannel process technology
|
US7307104B2
(en)
|
2003-05-16 |
2007-12-11 |
Velocys, Inc. |
Process for forming an emulsion using microchannel process technology
|
US7691838B2
(en)
|
2003-05-30 |
2010-04-06 |
Kosan Biosciences Incorporated |
Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
|
US20050020546A1
(en)
*
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
US20060189586A1
(en)
*
|
2003-06-11 |
2006-08-24 |
Cleland Jeffrey L |
Pharmaceutical compositions comprising active vitamin D compounds
|
EP1498120A1
(en)
*
|
2003-07-18 |
2005-01-19 |
Aventis Pharma S.A. |
Semi-solid formulations for the oral administration of taxoids
|
US20060292186A1
(en)
*
|
2003-08-29 |
2006-12-28 |
Novagali Pharma Sa |
Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
|
EP1510206A1
(en)
*
|
2003-08-29 |
2005-03-02 |
Novagali Pharma SA |
Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
|
US20050107465A1
(en)
*
|
2003-10-01 |
2005-05-19 |
Papas Andreas M. |
Composition for treating inflammatory bowel disease
|
US20050074444A1
(en)
*
|
2003-10-01 |
2005-04-07 |
Papas Andreas M. |
Coenzyme Q10 treatment for cystic fibrosis
|
CN100471886C
(zh)
*
|
2003-10-10 |
2009-03-25 |
株式会社三养社 |
两亲嵌段共聚物以及包含它的用于给药的聚合组合物
|
JP4235226B2
(ja)
*
|
2003-10-10 |
2009-03-11 |
サムヤン コーポレイション |
両親媒性ブロック共重合体及びそれを含む薬剤送達用高分子組成物
|
US7311901B2
(en)
*
|
2003-10-10 |
2007-12-25 |
Samyang Corporation |
Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
|
DE10347994A1
(de)
*
|
2003-10-15 |
2005-06-16 |
Pari GmbH Spezialisten für effektive Inhalation |
Wässrige Aerosol-Zubereitung
|
AU2004285037B2
(en)
*
|
2003-10-29 |
2010-07-22 |
Sonus Pharmaceuticals, Inc. |
Tocopherol-modified therapeutic drug compounds
|
US20080045559A1
(en)
*
|
2003-10-29 |
2008-02-21 |
Sonus Pharmaceuticals, Inc. |
Tocopherol-modified therapeutic drug compounds
|
US20050096365A1
(en)
*
|
2003-11-03 |
2005-05-05 |
David Fikstad |
Pharmaceutical compositions with synchronized solubilizer release
|
US20060003002A1
(en)
*
|
2003-11-03 |
2006-01-05 |
Lipocine, Inc. |
Pharmaceutical compositions with synchronized solubilizer release
|
TWI350183B
(en)
*
|
2003-12-31 |
2011-10-11 |
Ind Tech Res Inst |
A liposome and a preparation method
|
US20050158329A1
(en)
*
|
2004-01-21 |
2005-07-21 |
Ghosh Swapan K. |
Novel phytol derived immunoadjuvants and their use in vaccine formulations
|
EP1720551B9
(en)
*
|
2004-03-03 |
2011-09-21 |
Vital Health Sciences Pty Ltd. |
Alkaloid formulations
|
US20050209315A1
(en)
*
|
2004-03-20 |
2005-09-22 |
Papas Andreas M |
Bioavailable nutritional supplement and method of treatment of malabsorption
|
US8003122B2
(en)
*
|
2004-03-31 |
2011-08-23 |
Cordis Corporation |
Device for local and/or regional delivery employing liquid formulations of therapeutic agents
|
US7989490B2
(en)
|
2004-06-02 |
2011-08-02 |
Cordis Corporation |
Injectable formulations of taxanes for cad treatment
|
US20050220866A1
(en)
*
|
2004-04-02 |
2005-10-06 |
Dr. Reddy's Laboratories Limited |
Novel capsule formulations of etoposide for oral use
|
US20050226932A1
(en)
*
|
2004-04-09 |
2005-10-13 |
Samyang Corporation |
Pharmaceutical formulations for itraconazole
|
KR20050099311A
(ko)
*
|
2004-04-09 |
2005-10-13 |
에이엔에이치 케어연구소(주) |
주사제용 항암제 조성물
|
WO2005112977A2
(en)
*
|
2004-04-23 |
2005-12-01 |
Pharmain, Ltd. |
Compositions for treatment with glucagon-like peptide, and methods of making and using the same
|
TW200538181A
(en)
|
2004-05-18 |
2005-12-01 |
Brni Neurosciences Inst |
Treatment of depressive disorders
|
KR100582604B1
(ko)
|
2004-06-16 |
2006-05-23 |
보람제약주식회사 |
항산화제를 포함한 이부프로펜 및 덱시부프로펜의마이크로 에멀젼과 이를 이용한 투명 액제 및 투명연질캡슐 제제
|
KR20070059072A
(ko)
*
|
2004-07-28 |
2007-06-11 |
에스디 파마슈티칼스 인코포레이티드 |
알파 토코페릴 석시네이트, 이의 동족체 및 이의 염의안정한 주사용 조성물
|
BRPI0513673B8
(pt)
*
|
2004-08-03 |
2021-07-27 |
Vital Health Sciences Pty Ltd |
método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
|
KR100623013B1
(ko)
*
|
2004-09-04 |
2006-09-19 |
김영대 |
나노에멀션, 그의 용도 및 제조방법
|
US8557861B2
(en)
*
|
2004-09-28 |
2013-10-15 |
Mast Therapeutics, Inc. |
Low oil emulsion compositions for delivering taxoids and other insoluble drugs
|
US20060165769A1
(en)
*
|
2004-09-30 |
2006-07-27 |
Hyatt John A |
Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
|
CA2582378C
(en)
|
2004-10-01 |
2013-12-10 |
Velocys, Inc. |
Multiphase mixing process using microchannel process technology
|
US20080038316A1
(en)
*
|
2004-10-01 |
2008-02-14 |
Wong Vernon G |
Conveniently implantable sustained release drug compositions
|
US20060088558A1
(en)
*
|
2004-10-26 |
2006-04-27 |
Robert Jandzinski |
Vitamin E TPGS fluid concentrate comprising a low percentage of water
|
WO2006057895A2
(en)
*
|
2004-11-17 |
2006-06-01 |
Velocys Inc. |
Process for making or treating an emulsion using microchannel technology
|
GT200500310A
(es)
|
2004-11-19 |
2006-06-19 |
|
Compuestos organicos
|
US20060147518A1
(en)
*
|
2004-12-30 |
2006-07-06 |
Pierre Fabre Medicament |
Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
|
JP4877899B2
(ja)
*
|
2005-01-25 |
2012-02-15 |
学校法人近畿大学 |
薬物徐放出性球状微粒子及びその製造方法
|
US20090239827A1
(en)
*
|
2005-03-03 |
2009-09-24 |
Esra Ogru |
Compounds having lipid lowering properties
|
US20060222716A1
(en)
*
|
2005-04-01 |
2006-10-05 |
Joseph Schwarz |
Colloidal solid lipid vehicle for pharmaceutical use
|
EP1871343A2
(en)
*
|
2005-04-12 |
2008-01-02 |
Wisconsin Alumni Research Foundation |
Micelle composition of polymer and passenger drug
|
US20060240051A1
(en)
*
|
2005-04-26 |
2006-10-26 |
Singleton Andy H |
Eutectic blends containing a water soluble vitamin derivative
|
US7691392B2
(en)
|
2005-04-29 |
2010-04-06 |
Kosan Biosciences Incorporated |
Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either
|
WO2006134864A1
(ja)
*
|
2005-06-13 |
2006-12-21 |
Dainippon Sumitomo Pharma Co., Ltd. |
可溶化型製剤
|
KR20080019228A
(ko)
*
|
2005-06-17 |
2008-03-03 |
바이탈 헬스 사이언시즈 피티와이 리미티드 |
하나 이상의 디 및/또는 모노-(전자전달제) 인산염 유도체또는 그의 착염을 함유하는 담체
|
KR20130122630A
(ko)
|
2005-07-29 |
2013-11-07 |
블랜체트 록펠러 뉴로사이언시즈 인스티튜트 |
단독의 또는 pkc 억제제와 배합된 pkc 활성화제의 장기 기억 향상을 위한 용도
|
AU2006280511A1
(en)
*
|
2005-08-12 |
2007-02-22 |
Astrazeneca Ab |
Process
|
ATE538139T1
(de)
*
|
2005-08-30 |
2012-01-15 |
Lanxess Deutschland Gmbh |
Verwendung von katalysatoren für den metatheseabbau von nitrilkautschuk
|
US20090306198A1
(en)
*
|
2005-09-16 |
2009-12-10 |
Robert Nicolosi |
Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner
|
JP2009513642A
(ja)
*
|
2005-10-25 |
2009-04-02 |
アボット・ラボラトリーズ |
低水溶解度の薬剤を含む製剤およびそれの使用方法
|
WO2007056424A2
(en)
*
|
2005-11-07 |
2007-05-18 |
Penwest Pharmaceuticals, Co. |
Controlled-release emulsion compositions
|
US8022054B2
(en)
|
2005-11-28 |
2011-09-20 |
Marinus Pharmaceuticals |
Liquid ganaxolone formulations and methods for the making and use thereof
|
EP1965787B1
(en)
*
|
2005-11-30 |
2013-04-10 |
Endo Pharmaceuticals Inc. |
Treatment of xerostomia with a sulfur-containing antioxidant
|
US9486408B2
(en)
|
2005-12-01 |
2016-11-08 |
University Of Massachusetts Lowell |
Botulinum nanoemulsions
|
CA2896083A1
(en)
|
2005-12-08 |
2007-06-14 |
Insmed Incorporated |
Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
|
JP2009520040A
(ja)
|
2005-12-19 |
2009-05-21 |
ファーマイン コーポレーション |
治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
|
CN101011355B
(zh)
|
2006-02-01 |
2013-01-02 |
陈献 |
经维生素e琥珀酸酯稳定的医药组合物、其制备及用途
|
TWI376239B
(en)
*
|
2006-02-01 |
2012-11-11 |
Andrew Xian Chen |
Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
|
PT1993515E
(pt)
*
|
2006-03-10 |
2009-11-05 |
Laboswiss Ag |
Um método para solubilização, dispersão e estabilização de compostos, produtos obtidos por esse método, assim como a sua utilização
|
CA2649388A1
(en)
|
2006-04-20 |
2007-11-01 |
Velocys, Inc. |
Process for treating and/or forming a non-newtonian fluid using microchannel process technology
|
US8112292B2
(en)
|
2006-04-21 |
2012-02-07 |
Medtronic Navigation, Inc. |
Method and apparatus for optimizing a therapy
|
KR100917809B1
(ko)
|
2006-05-22 |
2009-09-18 |
에스케이케미칼주식회사 |
우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
|
EP2056818B1
(en)
|
2006-08-11 |
2011-05-25 |
The Johns Hopkins University |
Compositions and methods for neuroprotection
|
CA2847852A1
(en)
|
2006-09-22 |
2008-04-03 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US8660635B2
(en)
|
2006-09-29 |
2014-02-25 |
Medtronic, Inc. |
Method and apparatus for optimizing a computer assisted surgical procedure
|
WO2008063581A2
(en)
*
|
2006-11-20 |
2008-05-29 |
Lutonix, Inc. |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US8430055B2
(en)
|
2008-08-29 |
2013-04-30 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
US8414909B2
(en)
*
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
WO2008066899A2
(en)
|
2006-11-28 |
2008-06-05 |
Marinus Pharmaceuticals |
Nanoparticulate formulations and methods for the making and use thereof
|
EP2099429A2
(en)
|
2006-12-01 |
2009-09-16 |
Anterios, Inc. |
Micellar nanoparticles comprising botulinum toxin
|
WO2008088037A1
(ja)
*
|
2007-01-18 |
2008-07-24 |
National University Corporation Chiba University |
微粒子製剤
|
EP2121000B1
(en)
*
|
2007-02-09 |
2015-09-23 |
Blanchette Rockefeller Neurosciences, Institute |
Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
|
JP2010517759A
(ja)
*
|
2007-02-09 |
2010-05-27 |
アストラゼネカ・アクチエボラーグ |
水性媒体中における固体非晶質サブミクロン粒子の安定な分散体を製造する方法
|
CN101244053B
(zh)
*
|
2007-02-16 |
2010-12-08 |
石药集团中奇制药技术(石家庄)有限公司 |
以多西他赛为主组分的新的分散体系
|
US20080227805A1
(en)
*
|
2007-02-28 |
2008-09-18 |
Abbott Laboratories |
Sustained release parenteral formulations of buprenorphine
|
WO2008137717A1
(en)
|
2007-05-04 |
2008-11-13 |
Transave, Inc. |
Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
NZ581589A
(en)
*
|
2007-06-22 |
2012-10-26 |
Scidose Llc |
Solubilized sterile injectable formulation of docetaxel without Tween 80
|
US7960336B2
(en)
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
US8563527B2
(en)
|
2007-08-20 |
2013-10-22 |
Pharmain Corporation |
Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
|
JP5411141B2
(ja)
|
2007-09-10 |
2014-02-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
AU2008310956B2
(en)
|
2007-10-08 |
2014-08-07 |
Aurinia Pharmaceuticals Inc. |
Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
|
US20090130198A1
(en)
|
2007-11-21 |
2009-05-21 |
Innopharmax Inc. |
Pharmaceutical composition with enhanced bioavailability
|
WO2009087678A2
(en)
*
|
2007-12-24 |
2009-07-16 |
Sun Pharma Advanced Research Company Limited |
Nanodispersion
|
US20090176892A1
(en)
*
|
2008-01-09 |
2009-07-09 |
Pharmain Corporation |
Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
|
CN101519404B
(zh)
|
2008-02-29 |
2016-01-20 |
唐莉 |
15环噻酮衍生物及其制备方法与应用
|
CN102036661B
(zh)
|
2008-03-20 |
2016-12-28 |
维尔恩公司 |
维生素衍生物及其用途
|
ES2396946T3
(es)
|
2008-03-20 |
2013-03-01 |
Virun, Inc. |
Emulsiones que comprenden un derivado de PEG de tocoferol
|
DE102008015366A1
(de)
*
|
2008-03-20 |
2009-09-24 |
Merck Patent Gmbh |
Lyophilisierte Nanoemulsion
|
CN101998828A
(zh)
*
|
2008-03-28 |
2011-03-30 |
粒子科学有限公司 |
用于使治疗剂增溶的药物溶液和方法
|
US8409601B2
(en)
*
|
2008-03-31 |
2013-04-02 |
Cordis Corporation |
Rapamycin coated expandable devices
|
US8420110B2
(en)
*
|
2008-03-31 |
2013-04-16 |
Cordis Corporation |
Drug coated expandable devices
|
US8603531B2
(en)
|
2008-06-02 |
2013-12-10 |
Cedars-Sinai Medical Center |
Nanometer-sized prodrugs of NSAIDs
|
WO2009158678A1
(en)
|
2008-06-27 |
2009-12-30 |
Children's Hospital & Research Center At Oakland |
Lipophilic nucleic acid delivery vehicle and methods of use therefor
|
WO2010009075A1
(en)
*
|
2008-07-14 |
2010-01-21 |
The University Of North Carolina At Chapel Hill |
Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds
|
FR2933871B1
(fr)
*
|
2008-07-18 |
2012-12-14 |
Yvery |
Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe
|
BRPI0917719A2
(pt)
|
2008-08-27 |
2019-11-19 |
Calcimedica Inc |
compostos que modulam cálcio intracelular
|
AU2009293186A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Purdue Research Foundation |
Long-chain carboxychromanols and analogs for use as anti-inflammatory agents
|
US9676744B2
(en)
|
2008-09-19 |
2017-06-13 |
Purdue Research Foundation |
Long-chain carboxychromanols and analogs for use as anti-inflammatory agents
|
US8165658B2
(en)
*
|
2008-09-26 |
2012-04-24 |
Medtronic, Inc. |
Method and apparatus for positioning a guide relative to a base
|
US20140105822A1
(en)
*
|
2008-11-24 |
2014-04-17 |
Cedars-Sinai Medical Center |
Nanospheres comprising tocopherol, an amphiphilic spacer and a therapeutic or imaging agent
|
WO2010071866A2
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Combination therapy for arthritis with tranilast
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
JP5339980B2
(ja)
*
|
2009-03-23 |
2013-11-13 |
富士フイルム株式会社 |
分散組成物及び分散組成物の製造方法
|
AU2010259184B2
(en)
*
|
2009-06-09 |
2015-08-13 |
Aurinia Pharmaceuticals Inc. |
Topical drug delivery systems for ophthalmic use
|
WO2010146606A1
(en)
|
2009-06-19 |
2010-12-23 |
Sun Pharma Advanced Research Company Ltd., |
Nanodispersion of a drug and process for its preparation
|
WO2011043980A1
(en)
|
2009-10-07 |
2011-04-14 |
Sanford Burnham Medical Research Institute |
Methods and compositions related to clot-binding lipid compounds
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
US7772274B1
(en)
|
2009-10-19 |
2010-08-10 |
Scidose, Llc |
Docetaxel formulations with lipoic acid
|
US8541465B2
(en)
*
|
2009-10-19 |
2013-09-24 |
Scidose, Llc |
Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
|
US8912228B2
(en)
|
2009-10-19 |
2014-12-16 |
Scidose Llc |
Docetaxel formulations with lipoic acid
|
US20110092579A1
(en)
*
|
2009-10-19 |
2011-04-21 |
Scidose Llc |
Solubilized formulation of docetaxel
|
US8476310B2
(en)
|
2009-10-19 |
2013-07-02 |
Scidose Llc |
Docetaxel formulations with lipoic acid
|
CN102101863B
(zh)
|
2009-12-17 |
2014-10-15 |
唐莉 |
新型环氧噻酮化合物及其制备方法和用途
|
US20110166214A1
(en)
|
2010-01-07 |
2011-07-07 |
Innopharma, Llc |
Methods and compositions for delivery of taxanes in stable oil-in-water emulsions
|
ES2999020T3
(en)
|
2010-02-05 |
2025-02-24 |
Phosphagenics Ltd |
Carrier comprising non-neutralised tocopheryl phosphate
|
TWI438009B
(zh)
*
|
2010-02-19 |
2014-05-21 |
Teikoku Pharma Usa Inc |
紫杉烷前-乳劑調配物及其製造與使用之方法
|
WO2011119228A1
(en)
*
|
2010-03-23 |
2011-09-29 |
Virun, Inc. |
Nanoemulsion including sucrose fatty acid ester
|
WO2011119863A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Onconova Therapeutics, Inc. |
Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
|
RU2553350C2
(ru)
|
2010-03-30 |
2015-06-10 |
Фосфейдженикс Лимитед |
Трансдермальные пластыри
|
US20130030237A1
(en)
|
2010-04-15 |
2013-01-31 |
Charles Theuer |
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
CA2797533A1
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
CA2798180A1
(en)
|
2010-05-03 |
2011-11-10 |
Teikoku Pharma Usa, Inc. |
Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
|
US20130259875A1
(en)
|
2010-05-11 |
2013-10-03 |
Questcor Pharmaceuticals, Inc. |
Acth for treatment of amyotrophic lateral sclerosis
|
WO2011146801A1
(en)
*
|
2010-05-20 |
2011-11-24 |
Synta Pharmaceuticals Corp. |
Formulation and dosing of hsp90 inhibitory compounds
|
NZ604040A
(en)
|
2010-06-03 |
2015-02-27 |
Pharmacyclics Inc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
US8741373B2
(en)
|
2010-06-21 |
2014-06-03 |
Virun, Inc. |
Compositions containing non-polar compounds
|
JP5916149B2
(ja)
|
2010-08-27 |
2016-05-11 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
US8796416B1
(en)
|
2010-10-25 |
2014-08-05 |
Questcor Pharmaceuticals, Inc |
ACTH prophylactic treatment of renal disorders
|
US8895537B2
(en)
|
2010-10-29 |
2014-11-25 |
Infirst Healthcare Ltd. |
Compositions and methods for treating cardiovascular diseases
|
US11224659B2
(en)
|
2010-10-29 |
2022-01-18 |
Infirst Healthcare Limited |
Solid solution compositions and use in severe pain
|
US9744132B2
(en)
|
2010-10-29 |
2017-08-29 |
Infirst Healthcare Limited |
Solid solution compositions and use in chronic inflammation
|
US9308213B2
(en)
|
2010-10-29 |
2016-04-12 |
Infirst Healthcare Limited |
Solid solution compositions and use in chronic inflammation
|
US10695432B2
(en)
|
2010-10-29 |
2020-06-30 |
Infirst Healthcare Limited |
Solid solution compositions and use in severe pain
|
US9504664B2
(en)
|
2010-10-29 |
2016-11-29 |
Infirst Healthcare Limited |
Compositions and methods for treating severe pain
|
US11730709B2
(en)
|
2010-10-29 |
2023-08-22 |
Infirst Healthcare Limited |
Compositions and methods for treating severe pain
|
US11202831B2
(en)
|
2010-10-29 |
2021-12-21 |
Infirst Healthcare Limited |
Solid solution compositions and use in cardiovascular disease
|
US9271950B2
(en)
|
2010-10-29 |
2016-03-01 |
Infirst Healthcare Limited |
Compositions for treating chronic inflammation and inflammatory diseases
|
US9737500B2
(en)
|
2010-10-29 |
2017-08-22 |
Infirst Healthcare Limited |
Compositions and methods for treating severe pain
|
US10695431B2
(en)
|
2010-10-29 |
2020-06-30 |
Infirst Healthcare Limited |
Solid solution compositions and use in cardiovascular disease
|
WO2012063182A1
(en)
*
|
2010-11-08 |
2012-05-18 |
Cadila Pharmaceuticals Limited |
Pharmaceutical composition of taxoids
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
EP2670390A2
(en)
*
|
2011-02-04 |
2013-12-11 |
Biocopea Limited |
Compostions and methods for treating chronic inflammation and inflammatory diseases
|
WO2012122586A1
(en)
|
2011-03-15 |
2012-09-20 |
Phosphagenics Limited |
New composition
|
AU2012332424A1
(en)
|
2011-11-02 |
2014-06-05 |
Synta Pharmaceuticals Corp. |
Combination therapy of Hsp90 inhibitors with platinum-containing agents
|
US9439899B2
(en)
|
2011-11-02 |
2016-09-13 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
|
US9717678B2
(en)
*
|
2011-11-06 |
2017-08-01 |
Murty Pharmaceuticals, Inc. |
Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts
|
EP2780010A1
(en)
|
2011-11-14 |
2014-09-24 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
SG11201404640YA
(en)
|
2012-02-10 |
2014-09-26 |
Virun Inc |
Beverage compositions containing non-polar compounds
|
US20130226550A1
(en)
*
|
2012-02-23 |
2013-08-29 |
Hassan Benameur |
Systems and methods for modeling compound formulations
|
EP4005576B1
(en)
|
2012-05-21 |
2023-12-13 |
Insmed Incorporated |
Systems for treating pulmonary infections
|
AR091858A1
(es)
|
2012-07-25 |
2015-03-04 |
Sova Pharmaceuticals Inc |
INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
|
AR091857A1
(es)
|
2012-07-25 |
2015-03-04 |
Sova Pharmaceuticals Inc |
INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
|
JO3685B1
(ar)
|
2012-10-01 |
2020-08-27 |
Teikoku Pharma Usa Inc |
صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
MX2015006681A
(es)
|
2012-11-29 |
2016-04-06 |
Insmed Inc |
Formulaciones de vancomicina estabilizadas.
|
CA2895357C
(en)
*
|
2012-12-21 |
2020-01-07 |
National Health Research Institutes |
Mesoporous silica nanoparticles for oil absorption
|
JP6122646B2
(ja)
*
|
2013-01-23 |
2017-04-26 |
昭和電工株式会社 |
皮膚外用剤
|
US10232018B2
(en)
|
2013-03-14 |
2019-03-19 |
Mallinckrodt Ard Ip Limited |
ACTH for treatment of acute respiratory distress syndrome
|
US9351517B2
(en)
|
2013-03-15 |
2016-05-31 |
Virun, Inc. |
Formulations of water-soluble derivatives of vitamin E and compositions containing same
|
WO2014165672A1
(en)
*
|
2013-04-06 |
2014-10-09 |
Igdrasol, Inc. |
Nanoparticle therapeutic agents, their formulations, and methods of their use
|
US9585417B2
(en)
*
|
2013-06-20 |
2017-03-07 |
Vitasome Labs, Inc. |
Dietary supplement compositions with enhanced delivery matrix, and methods of making the same
|
US10299492B2
(en)
*
|
2013-06-20 |
2019-05-28 |
James John YIANNIOS |
Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same
|
US11044923B2
(en)
|
2013-06-20 |
2021-06-29 |
Vitasome Labs, Inc. |
Gummies containing formulations with enhanced delivery matrix, and methods of making same
|
US12256756B2
(en)
|
2013-06-20 |
2025-03-25 |
Vitasome Labs LLC. |
Gummies containing formulations with enhanced delivery matrix, and methods of making same
|
US9693574B2
(en)
|
2013-08-08 |
2017-07-04 |
Virun, Inc. |
Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
|
US9896403B2
(en)
*
|
2014-08-22 |
2018-02-20 |
Ironstone Separations, Inc. |
Solubilization of pterostilbene and resveratrol in aqueous beverages
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JP6345786B2
(ja)
|
2013-12-05 |
2018-06-20 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼの阻害剤
|
KR102489036B1
(ko)
|
2014-05-15 |
2023-01-13 |
인스메드 인코포레이티드 |
폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
WO2016033549A2
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US10016363B2
(en)
|
2014-09-18 |
2018-07-10 |
Virun, Inc. |
Pre-spray emulsions and powders containing non-polar compounds
|
US9861611B2
(en)
|
2014-09-18 |
2018-01-09 |
Virun, Inc. |
Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
MY182652A
(en)
*
|
2014-11-25 |
2021-01-27 |
Kl Kepong Oleomas Sdn Bhd |
Formulation for effective tocotrienol delivery
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
US20160250270A1
(en)
|
2015-02-27 |
2016-09-01 |
Ebbu, LLC |
Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
|
EP3261631B1
(en)
|
2015-02-27 |
2025-09-10 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
US20180098936A1
(en)
*
|
2015-03-23 |
2018-04-12 |
President And Fellows Of Harvard College |
Methods and compositions for injecting high concentration and/or high viscosity active agent solutions
|
US20160361322A1
(en)
|
2015-06-15 |
2016-12-15 |
Lipocine Inc. |
Composition and method for oral delivery of androgen prodrugs
|
CA2996177A1
(en)
|
2015-08-31 |
2017-03-09 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
TWI838700B
(zh)
|
2015-09-30 |
2024-04-11 |
香港商慧源香港創新有限公司 |
口服紫杉烷組合物及方法
|
US9637514B1
(en)
|
2015-10-26 |
2017-05-02 |
MAX BioPharma, Inc. |
Oxysterols and hedgehog signaling
|
EP3368543B1
(en)
|
2015-10-26 |
2020-09-23 |
MAX Biopharma, Inc. |
Oxysterols and hedgehog signaling
|
CN108601732A
(zh)
*
|
2015-12-09 |
2018-09-28 |
磷肌酸有限公司 |
药物制剂
|
WO2017119928A1
(en)
*
|
2016-01-08 |
2017-07-13 |
Abon Pharmaceuticals, Llc |
Long acting injectable formulations
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
CN109310700A
(zh)
|
2016-04-04 |
2019-02-05 |
希诺皮亚生物科学公司 |
使用曲匹地尔治疗锥体外系综合征
|
AU2017263574B2
(en)
|
2016-05-12 |
2022-11-17 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
WO2017205534A1
(en)
|
2016-05-25 |
2017-11-30 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
SG11201901679XA
(en)
|
2016-08-26 |
2019-03-28 |
Curtana Pharmaceuticals Inc |
Inhibition of olig2 activity
|
CA3034004C
(en)
|
2016-08-29 |
2021-08-03 |
Canopy Growth Corporation |
Water soluble compositions comprising purified cannabinoids
|
CA3044219A1
(en)
|
2016-11-21 |
2018-05-24 |
Eirion Therapeutics, Inc. |
Transdermal delivery of large agents
|
EP3544614A4
(en)
|
2016-11-28 |
2020-08-05 |
Lipocine Inc. |
TESTOSTERONE UNDECANOATE ORAL TREATMENT
|
CN110662733A
(zh)
|
2016-12-21 |
2020-01-07 |
埃维科生物技术有限公司 |
方法
|
WO2018129345A1
(en)
|
2017-01-08 |
2018-07-12 |
Resq Pharma, Inc. |
Methods for decreasing injuries associated with intraoperative hypotension
|
US20190224275A1
(en)
|
2017-05-12 |
2019-07-25 |
Aurinia Pharmaceuticals Inc. |
Protocol for treatment of lupus nephritis
|
CN112739345A
(zh)
|
2017-11-06 |
2021-04-30 |
斯奈普生物公司 |
Pim激酶抑制剂组合物,方法和其用途
|
WO2019094773A1
(en)
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
CA3084809A1
(en)
|
2017-12-07 |
2019-06-13 |
The Regents Of The University Of Michigan |
Nsd family inhibitors and methods of treatment therewith
|
EP3508562A1
(en)
*
|
2018-01-05 |
2019-07-10 |
Castrol Limited |
Micellar emulsions
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
WO2019191627A1
(en)
|
2018-03-30 |
2019-10-03 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
HUE063908T2
(hu)
|
2018-04-30 |
2024-02-28 |
Cedars Sinai Medical Center |
Módszerek és rendszerek gyulladásos betegségekben szenvedõ betegek kiválasztására és kezelésére
|
US20210121401A1
(en)
*
|
2018-05-25 |
2021-04-29 |
Resq Pharma, Inc. |
Lipid emulsions and uses thereof
|
JP2021527064A
(ja)
|
2018-06-07 |
2021-10-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Prc1阻害剤及びそれを用いた治療方法
|
WO2020010139A1
(en)
|
2018-07-06 |
2020-01-09 |
Cedars-Sinai Medical Center |
Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
|
US12150945B2
(en)
|
2018-07-20 |
2024-11-26 |
Lipocine Inc. |
Liver disease
|
TW202019887A
(zh)
|
2018-07-27 |
2020-06-01 |
美商同心止痛劑股份有限公司 |
酚系trpv1促效劑之聚乙二醇化前藥
|
WO2020046466A1
(en)
|
2018-08-29 |
2020-03-05 |
Myos Rens Technology, Inc. |
Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
|
MX2021003084A
(es)
|
2018-09-20 |
2021-08-11 |
Forge Therapeutics Inc |
Compuestos antibacterianos.
|
CA3114061A1
(en)
*
|
2018-09-25 |
2020-04-02 |
Tolmar International, Ltd. |
Liquid polymer delivery system for extended administration of drugs
|
US12251405B2
(en)
|
2018-10-03 |
2025-03-18 |
Myos Corp. |
Spray dried follistatin product
|
WO2020096660A1
(en)
|
2018-11-06 |
2020-05-14 |
Myos Rens Technology, Inc. |
Methods and compositions for improving skeletal muscle protein fractional synthetic rate
|
WO2020135920A1
(en)
*
|
2018-12-28 |
2020-07-02 |
Université Libre de Bruxelles |
Kit for inhaled chemotherapy, and treatment of lung cancer with said kit
|
MX2021007925A
(es)
|
2018-12-31 |
2021-10-26 |
Biomea Fusion Llc |
Inhibidores irreversibles de la interaccion menina-mll.
|
US11833186B2
(en)
|
2019-02-01 |
2023-12-05 |
Myos Corp. |
Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
|
US12377082B2
(en)
|
2019-03-15 |
2025-08-05 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
CA3140029A1
(en)
|
2019-05-14 |
2020-11-19 |
Prometheus Biosciences, Inc. |
Tl1a patient selection methods, systems, and devices
|
MA56541A
(fr)
|
2019-06-21 |
2022-04-27 |
Entelexo Biotherapeutics Inc |
Plateformes, compositions et méthodes d'administration de composés thérapeutiques
|
US11731962B2
(en)
|
2020-03-25 |
2023-08-22 |
Blacksmith Medicines, Inc. |
LpxC inhibitor and methods of making
|
US20210315902A1
(en)
*
|
2020-03-25 |
2021-10-14 |
Forge Therapeutics, Inc. |
Lpxc inhibitor, formulations, and uses thereof
|
EP4161492A1
(en)
*
|
2020-06-05 |
2023-04-12 |
University Of Cyprus |
Therapeutic nanocarrier system and methods of use
|
US11858925B2
(en)
|
2020-07-10 |
2024-01-02 |
The Regents Of The University Of Michigan |
GAS41 inhibitors and methods of use thereof
|
WO2022066600A1
(en)
*
|
2020-09-22 |
2022-03-31 |
Micronization Technologies And Therapeutics Group Llc |
Nebulizer and nebulized anti-virals
|
EP4263542A1
(en)
|
2020-12-16 |
2023-10-25 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
AU2022325861A1
(en)
|
2021-08-11 |
2024-02-29 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
US20240409558A1
(en)
|
2021-09-13 |
2024-12-12 |
Biomea Fusion, Inc. |
Irreversible inhibitors of kras
|
CA3233328A1
(en)
|
2021-09-28 |
2023-04-06 |
Min Teng |
Lpxc inhibitors and uses thereof
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
WO2023119230A1
(en)
|
2021-12-22 |
2023-06-29 |
L'oreal |
Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
|
PE20242008A1
(es)
|
2021-12-30 |
2024-10-03 |
Biomea Fusion Inc |
Compuestos de pirazina como inhibidores de flt3
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
AU2023363975A1
(en)
|
2022-10-19 |
2025-05-22 |
Myos Corp. |
Myogenic compounds
|
US20250002458A1
(en)
|
2023-05-24 |
2025-01-02 |
Unicycive Therapeutics Inc. |
Salt forms of nicorandil derivative
|
WO2024249950A1
(en)
|
2023-06-02 |
2024-12-05 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
WO2025072556A1
(en)
|
2023-09-26 |
2025-04-03 |
Unicycive Therapeutics, Inc. |
Amino acid prodrugs of nicorandil
|